Healthcare -
Biotechnology - NASDAQ - US
$ 0.5558
0.999 %
$ 57.7 M
Market Cap
-1.21
P/E
1. INTRINSIC VALUE
Balance Sheet
Unicycive Therapeutics, Inc.
| Current Assets | 13.4 M |
| Cash & Short-Term Investments | 9.7 M |
| Receivables | 0 |
| Other Current Assets | 3.7 M |
| Non-Current Assets | 792 K |
| Long-Term Investments | 0 |
| PP&E | 792 K |
| Other Non-Current Assets | 0 |
| Current Liabilities | 17.5 M |
| Accounts Payable | 821 K |
| Short-Term Debt | 345 K |
| Other Current Liabilities | 16.4 M |
| Non-Current Liabilities | 466 K |
| Long-Term Debt | 466 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Unicycive Therapeutics, Inc.
| Revenue | 675 K |
| Cost Of Revenue | 0 |
| Gross Profit | 675 K |
| Operating Expenses | 21.4 M |
| Operating Income | -20.8 M |
| Other Expenses | 9.77 M |
| Net Income | -30.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Unicycive Therapeutics, Inc.
| Net Income | -30.5 M |
| Depreciation & Amortization | 284 K |
| Capital Expenditures | -12 K |
| Stock-Based Compensation | 1.77 M |
| Change in Working Capital | -93 K |
| Others | 8.93 M |
| Free Cash Flow | -18.3 M |
Wall Street Analysts Price Targets
Unicycive Therapeutics, Inc.
UNCY has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
UNCY does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Unicycive Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 years ago
May 16, 2022
|
Bought
12.4 K USD
|
Schiller Brigitte
director:
|
+ 15000
|
0.825 USD |
7. News
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
LOS ALTOS, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the publication of preclinical data describing the benefits of combination treatment of oxylanthanum carbonate (OLC) and tenapanor on phosphate management in the American Society of Nephrology (ASN) journal, Kidney360.
globenewswire.com
- 1 week ago
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherence Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherence
globenewswire.com
- 1 month ago
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
LOS ALTOS, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that data from the Company's oxylanthanum carbonate (OLC) Phase 1 dose escalation study in healthy volunteers was published in the peer-reviewed journal, Clinical and Translational Science.
globenewswire.com
- 1 month ago
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
LOS ALTOS, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investment conferences in December.
globenewswire.com
- 3 months ago
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
– OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025– – Commercial Planning in Progress for 2025 Launch – – Late Breaker Poster Presentation on OLC at ASN Kidney Week – – Successful Completion of UNI-494 Phase 1 Trial – LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2024, and provided a business update.
globenewswire.com
- 3 months ago
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
– FDA sets PDUFA Action Date of June 28, 2025 – Company Preparing for 2025 Commercial Launch – LOS ALTOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025.
globenewswire.com
- 3 months ago
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and UNI-494 – LOS ALTOS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that multiple presentations were delivered at the American Society of Nephrology (ASN) Kidney Week 2024 that highlighted the extensive development progress for both oxylanthanum carbonate (OLC) and UNI-494.
globenewswire.com
- 4 months ago
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 at 10:00 a.m. ET.
globenewswire.com
- 4 months ago
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
LOS ALTOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that a poster presentation on oxylanthanum carbonate (OLC) was selected for a Late-Breaker session at the American Society of Nephrology (ASN) Kidney Week 2024. Unicycive will also deliver three additional poster presentations on OLC and UNI-494. The conference will take place October 24-27, 2024 in San Diego, CA.
globenewswire.com
- 4 months ago
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
UNI-494 was Well-Tolerated as a Single Dose up to 160 mg and in Multiple Doses at 40 mg Twice-a-Day UNI-494 was Well-Tolerated as a Single Dose up to 160 mg and in Multiple Doses at 40 mg Twice-a-Day
globenewswire.com
- 4 months ago
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
LOS ALTOS, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the virtual Lytham Partners Fall 2024 Investor Conference on Tuesday, October 1, 2024 at 11:00 a.m. ET.
globenewswire.com
- 5 months ago
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
LOS ALTOS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company" or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the Virtual Life Sciences Investor Forum on Thursday, September 19, 2024 at 2:00 p.m. ET in New York, NY.
globenewswire.com
- 5 months ago
8. Profile
Summary
Unicycive Therapeutics, Inc. UNCY
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 57.7 M
Dividend Yield
0.00%
Description
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Contact
4300 El Camino Real, Los Altos, CA, 94022
https://www.unicycive.com
IPO
Date
July 12, 2021
Employees
14
Officers
Dr. Pramod Gupta Ph.D.
Executive Vice President of Pharmaceutical & Business Operations
Dr. Shalabh K. Gupta M.D., MPA
Founder, Chairman, Chief Executive Officer & President
Mr. Douglas Jermasek M.B.A.
Executive Vice President of Corporate Strategy
Mr. John W. Townsend CPA
Chief Financial Officer